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ABSTRACT 
INVESTIGATING THE PATTERNS AND MECHANISMS OF ALTERNATIVE 
SPLICING OF CAV1.3 IN THE MOUSE. 
Samuel Sabzanov 
 
L-type voltage-gated calcium channel Cav1.3 contains a pore-forming α-1 subunit that is 
encoded by Cacna1d, a gene which has been shown to undergo alternative splicing (AS). 
Mutations in CACNA1D have been associated with neurological diseases such as 
spontaneous seizure disorder and epilepsy. Previous studies have shown that AS of the C-
terminus of Cav1.3 results in a truncated variant of exon 42 (E42) that, when compared to 
the full-length exon, lowers the voltage threshold needed to activate the calcium channel. 
Therefore, AS of the a1-subunit can modulate the physiological properties of Cav1.3. As 
a lower voltage threshold of calcium channels increases neural excitability, AS of Cav1.3 
could have many clinical implications. 
Previous studies have also linked the alternatively spliced N-terminus of Cav1.3 to 
autism spectrum disorder (ASD). In a human patient study, naturally occurring missense 
mutations in mutually exclusive exons 8a and 8b have been correlated with various 
neurological disorders. These results highlight the important role that AS plays in Cav1.3 
function. We were able to confirm four alternatively spliced regions, E8-E11, E12-E15, 
E32-36, and E46-E48 in Cacna1d. By semi-quantitative RT-PCR analysis, we found that 
these alternatively spliced variants are expressed at higher levels in brain-derived tissues 
when compared to non-brain derived tissues. We were also able to construct minigenes of 
   
 
E13, E33-E34, E35, and E47 to test their regulation by common splicing factors (SF) Nova-
1, Nova-2, Ptbp-2, Rbfox-1, and Mbln2. While AS of Cav1.3 has been shown to play 
important roles in electrophysiological properties and neurological disorders, how AS of 
Cav1.3 is regulated remains poorly understood. Our results will serve to characterize the 
mechanism of AS in Cacna1d for future studies aimed at determining whether or not certain 
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Chapter 1: Introduction.   
Alternative Splicing Overview. RNA Splicing is one of the main processes in the 
maturation of mRNA. RNA Splicing involves the removal of intervening nucleotides, or 
introns, and the ligation of the remaining nucleotides, known as exons (Clancy, 2008). 
Splicing of immature mRNA, or pre-mRNA, is catalyzed by the formation of a large 
ribonucleoprotein complex called the spliceosome (Chen and Cheng, 2012). Each 
spliceosome is composed of five small nuclear RNAs and a range of associated protein 
factors. When these small nuclear RNAs are combined with the factors, they create RNA-
protein complexes that are called small nuclear ribonuclear proteins (snRNPs) (Will and 
Luhrmann, 2011). After an snRNP binds to the 5′ nucleotide splice site, the 5′ end of the 
intron pairs with a downstream 3’ branch, forming a loop, or lariat. The 3′ end of the exon 
is then cut and joined to the branch site by the free 3’ hydroxyl (OH) group. As a result, 
the exons are covalently bound, and the lariat containing the intron is released (Konarska 
et al 1985). Constitutive splicing is the process of intron removal and exon ligation in the 
order in which they appear on a gene. AS, on the other hand, is a deviation from this 
preferred sequence where certain exons are skipped resulting in various forms of mature 
mRNA (Wang et al 2015). AS events are mediated by multiple RNA-binding proteins (Fu 
and Ares, 2014).  
AS allows cells with the same genome to have different proteomes, as different 
protein isoforms can originate from the same pre-mRNA (Liu et al 2017). Proteomic 
diversity is a key contributor to cellular differentiation (van Hoof et al 2012), and 95% of 
human multi-exonic genes undergo AS (Chen and Manley, 2009). Interestingly, up to 50% 
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of pathogenic mutations are thought to work on the level of affecting splicing (Douglas 
and Wood, 2011). In ion channels, AS can generate isoforms that alter the channels 
electrophysiological properties (Cheng et al 2009). 
 
Splicing Factors Overview. SF are RNA-binding proteins that form snRNPs with pre-
mRNA (Chen and Cheng, 2012). In this study, we further characterize the regulation of 
AS events by the SF Nova-1, Nova-2, Ptbp2, Mbnl-2, and Rbfox-1. All of these SF are 
sequence specific, meaning that they have a known cis-acting regulatory element 
sequence that they bind to regulate AS(Fu and Ares, 2014). Nova-1 and Nova 2 are 
neuron specific SF that are highly homologous regulators of AS, and Nova proteins are 
known to regulate at least 700 AS in events in vivo (Saito et al 2016).  Via  RNA 
selection amplification, the high affinity binding site of Nova-1 was determined to be a 
YCAY motif, where Y=C/U (Buckanovich and Darnell, 1997). Nova proteins are 
exclusively expressed in central nervous system (CNS) neurons and are the target 
antigens in the autoimmune neurological disorder paraneoplastic opsoclonus myoclonus 
ataxia (POMA). POMA is associated with breast cancer and fallopian cancer and is 
characterized primarily by dysfunction of the motor nervous system. (Jensen et al 2000, 
Buckanovich and Darnell, 1997, Yang et al 1998). Nova-1 targets have also been shown 
to regulate the development of brain synapsis, showing a role for Nova-1 in 
neurodevelopment (Ule et al 2005). 
Both Nova-1 and Nova-2 were originally cloned from POMA patients (Yang et al 
1998, Buckanovich et al 1993 ), and they both bind to exonic and intronic regions Fu and 
Ares, 2014). Nova-2 is closely related to Nova-1 and is expressed at high levels in 
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neurons during development and in adulthood, and at lower levels in the adult lung (Yang 
et al 1998). NOVA-2-mediated RNA regulation is required for proper development of the 
neocortex and hippocampus, identifying a role for Nova-2 in neurodevelopment (Saito et 
al 2019). Nova-2, has a GAGUCAU motif, different from the YCAY motif of Nova-1, as 
verified by in vitro ribohomopolymer binding assays and RNA selection using Nova-2 
(Yang et al 1998, Buckanovich and Darnell, 1997). 
Polypyrimidine tract binding protein 2 (Ptbp-2; also known as nPTB or brPTB) is 
a known antagonist of Nova proteins (Polydorides et al 2000) and is primarily expressed 
in the brain (Licatalosi et al 2012). Ptbp-2 utilization of the intronic UCUY motif was 
characterized via the examination of sequence composition anchored at a cross-linking-
induced mutation site (CIMS). This motif is sharply enriched in specific positions around 
the CIMS, compared with flanking sequences (Licatalosi et al 2012). Ptbp-2 has been 
shown to promote the proliferation and migration of glioma cell lines (Cheung et al 
2009).  In the mouse brain, loss of Ptbp-2 leads to a catastrophic failure in neuronal 
maturation and to the misexpression of many protein isoforms that affect neurite growth, 
synapse formation and synaptic transmission. (Li et al 2014). A recent publication shows 
how an AS program orchestrated by Ptbp-2 is required for early axon formation in the 
mammalian cortex (Zhang et al 2019), further underlying the leading role for Ptbp-2 in 
neuronal development 
RNA binding Fox-1 homolog 1 (Rbfox-1) works via an intronic GCAUG motif to 
regulate AS in vertebrates. The function of this sequence was examined by gel shift 
experiments. When an RNA probe, which contained the GCAUG sequence, was used, 
strong binding of Rbfox-1 was observed, providing evidence for the use of the GCAUG 
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motif in Rbfox-1 (Jin et al 2003). Rbfox-1 has also been associated with 
neurodevelopmental and neuropsychiatric disorders such as intellectual disability, 
epilepsy, attention deficit hyperactivity disorder, and schizophrenia (Hamada et al 
2015). Moreover, Rbfox-1 promotes inclusion of a 60 nucleotide cassette exon of 
Cacna1d in the mouse brain (Gehman et al 2011) 
Muscle blind like splicing regulator 2 (Mbnl-2) regulates the developmental 
splicing of hundreds of alternative cassette exons via the recognition of an intronic 
YGCY motif in a manner reminiscent of the Nova, Rbfox and Ptbp splicing factor 
families, although the binding motifs for these factors are quite different. The YGCY 
motif was verified via de novo analysis using a 21-nt sequence around CIMS. This assay 
highlighted YGCY as a core element in all top motifs for Mbnl-2. Mbnl-2 knockout mice 
develop several myotonic dystrophy-associated CNS features including abnormal REM 
sleep propensity and deficits in spatial memory. Mbnl-2 is prominently expressed in the 
hippocampus and Mbnl-2 knockouts show impaired hippocampal synaptic plasticity. It is 
proposed that pathological features of the myotonic dystrophy brain result from 
disruption of the Mbnl-2-mediated developmental splicing program (Charizanis et al 
2013). Interestingly, Mbnl-2 appears to promote inclusion of Cacna1d cassette exon E12a 
in the mouse brain (Goodwin et al 2015).  
As described above, previous work with Nova-1,Nova-2, Ptbp-2, Mbnl-2, and 
Rbfox-1 have all shown a role for these SF in neuronal development. Also, both Mbnl-2 
and Rbfox-1 have been shown to regulate AS of the ion channel gene we are studying, 
Cav1.3 (Charizanis et al 2012, Gehman et al 2011, Goodwin et al 2015). As Cav1.3, has 
been shown to have a role in neuronal development (Pinggera and Striessnig, 2016), we 
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studied these SF to test their potential regulation of our alternatively spliced Cav1.3 
regions of interest.  
 
Cav1.3 Overview. There are two primary low voltage gated calcium channel (LVGCC) 
pore forming subunits that are expressed in the mammalian brain: Cav1.2, which 
compromises about 80% of total LVGCC expression, and Cav1.3, which accounts for the 
remaining 20% (Krueger et al 2017). Calcium ion influx through LVGCCs regulates 
numerous physiological functions, namely muscle contraction, hormone release, neuronal 
firing and plasticity, sensory function, and cardiac pace making (Catterall et al 2005). Four 
pore-forming a-1 subunit isoforms (Cav1.1–Cav1.4), each with different biophysical 
properties and expression profiles, evolved to adjust LVGCC calcium ion signaling to 
cellular needs. Cav1.3 channels play a unique role in hearing (sensory signaling in cochlear 
inner hair cells) and sinoatrial node (diastolic depolarization) function (Striessnig, 2007). 
Cav1.3 knockout mice show a reduced magnitude of prolonged periods of 
hyperpolarization, a phenomenon known as slow after hyperpolarization (sAHP) when 
compared to Cav1.3 WT mice. sAHP, a key determinant of neural excitability, is increased 
in neurons from aged animals as opposed to neurons of younger animals, which suggests 
an important role for Cav1.3 in aging (Krueger et al 2017).  In neurons, Cav1.3 channels 
have pacemaker function and can shape neuronal firing (Olson et al 2005, Helton et al 
2005).  
Alternative Splicing of Cav1.3 at the C-terminus. Calcium ion influx through LVGCCs 
is limited by a calcium dependent feedback mechanism, known as calcium-dependent 
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inactivation (CDI) (Halling et al 2005). CDI develops in response to local or global 
elevations in calcium ion concentration sensed by channel-bound calmodulin (Liang et al 
2003, Soldatov et al 1997). Both lobes of the calmodulin molecule are required for 
modulation by CDI (Banerjee et al 2018).  This modulation by CDI via channel-bound 
calmodulin is reduced by a C-terminal modulator, or CTM. Alternatively spliced variants 
of Cav1.3, termed Cav1.3 42 and Cav1.3 42A, differ in length at the end of the C-terminus, 
with the latter being a truncated variant. This truncated variant lacks most of a homologous 
region termed PCRD, or proximal C-terminal regulatory domain. The E42A variant which 
lacks the PCRD causes the channel to activate at more negative voltage potentials and is 
also more sensitive to calcium ion levels, showing a role for AS in modulating voltage-
dependent kinetics of the channel (Singh et al 2008). A set of Arginine residues in the 
PCRD interact with a set of two negative charges in a distal regulatory domain, termed 
DCRD, to form a functional CTM. The functional CTM has also been shown to reduce 
CDI of Cav1.3 and promote Cav1.3 activation at more negative voltages (Singh et al 2008).   
Alternative Splicing at the N-terminus: AS events also occur in the N-terminus of 
Cacna1d. Gain-of-function somatic missense mutations have been characterized in the 
alternatively spliced Cacna1d E8a and E8b. In E8a, missense mutation G407R has been 
characterized as a de novo gain-of-function mutation related to Autism Spectrum Disorder 
(ASD). In both E8a and E8b, missense mutation G403R was identified as a de novo 
germline mutation in two patients with primary aldosteronism, seizures and neurological 
abnormalities (Pinggera and Striessnig, 2016).  
6 
   
 
Objective 1: As all of these results highlight the important role that AS plays in Cav1.3 
function, we set out to characterize novel alternatively spliced variants of Cav1.3. We were 
able to confirm four alternatively spliced regions, E8-E11, E12-E15, E32-36, and E46-E48 
in Cacna1d, as seen in Figure 1. It should be noted that our annotation of Cacna1d are 
shifted in comparison to the commonly used annotations in Cav1.3-related literature. For 
example, E9 and E10 in this study are referred to in the literature as E8a and E8b. By semi-
quantitative RT-PCR analysis, we therefore set out to show that these alternatively spliced 
variants are expressed at higher levels in brain-derived tissues when compared to non-brain 
derived tissues. Our results serve to characterize the AS of Cav1.3 within its biophysically 
relevant C- and N-termini.  
 








Figure 1 Cav1.3 transmembrane domain. The transmembrane domain of Cav1.3 channels 
feature four homologous repeats with six transmembrane segments (1–6). A membrane-
associated loop between segments 5 and 6. Labeled numbers show the position of the amino 
acids that our characterized alternatively spliced regions encode for. Clinically significant 
amino acids G403 and G407 are seen right after the sixth transmembrane segment of the 
first homologous repeat of the Cav1.3’s transmembrane domain. Lower portion of the 




   
 
Objective 2: After our initial characterization of the variants, we successfully set out to 
construct minigenes (see Materials and Methods) of E13, E33-E34, E35, and E47 to test 
their regulation by a few well characterized SF: Nova-1, Nova-2, Ptbp-2, Rbfox-1, and 
Mbln2. Our collaborator on this project, Dr. Chaolin Zhang, developed a bioinformatics 
algorithm that, when combined with the extensive publicly available cross-linking 
immunoprecipitation (CLIP) datasets on these SF, allows the identification of genome-
wide putative cis-acting regulatory binding sites where these SF may bind on pre-mRNA 
to regulate AS (Weyn-Vanhentenryck et al 2014, Weyn-Vanhentenryck and Zhang, 
2016) . Similar integrative approaches have been recently applied successfully to the 
generation of large-scale maps of targets for hundreds of RNA-binding proteins and SFs, 
allowing the profiling of their binding specificities, the discovery of their regulatory 
networks, and the identification of novel principles of RNA biology and gene regulation 
(Dominguez et al 2028,  Van Nostrand et al 2020). The CLIP method combines UV-cross 
linking with immunoprecipitation to analyze protein-RNA interactions (Zhang & Darnell 
et al 2011, Ule et al 2003, Ule et al 2005, Licatalosi et al 2008). As some of the introns in 
our regions of interest are above 10 kb, we needed these putative sequences to effectively 
narrow down the region that may contain cis-acting regulatory sequences that mediate AS 
to design more compact minigenes that are more feasible to work with. While AS of 
Cav1.3 has been shown to play an important role in electrophysiology and the 
development of neurological disorders, how AS of Cav1.3 is regulated remains poorly 
understood. Our results serve to characterize the mechanism of AS in Cacna1d for future 
studies aimed at determining whether or not certain splice isoforms lead to changes in the 
channel’s electrophysiological properties.
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Chapter 2: Materials and Methods 
Transcript Scanning. We performed a three phase semi-quantitative reverse transcription 
(RT)-PCR using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). The 
first of these phases was an incubation at 65 °C for 5 minutes with 500ng of Oligo(dT), 
500ng of digested RNA, and RNAse-free diethylpolycarbonate (DEPC)-treated water for 
a total reaction volume of 12µL. The second phase reaction was an RT reaction. This 
reaction included the addition of 4µL of 5X RT Reaction Buffer (Thermo Scientific), 1µL 
of DEPC water, 2µL of 10mM dNTPs (Thermo Scientific), and 0.5µL each of 200 units/µL 
RT and 20units/µL RiboLock Enzymes (Thermo Scientific ) to the incubated solution from 
phase 1. The third phase reaction was the PCR. For this PCR, we added 5µL of 10X 
Maxima Hot Start Taq Buffer (Thermo Scientific), 0.4µL of 5 units/µL Maxima Hot Start 
Taq DNA Polymerase (Thermo Scientific), 3µL of 25mM MgCl2 cofactor (Thermo 
Scientific), 1µL of each 10uM primer, and DEPC water for a total reaction volume of 50µL.  
Conditions for the PCR were as follows: 60 °C annealing temperature, 30 second 
elongation per kilobase of DNA, for 32 cycles. Mouse organs used for semi-quantitative 
transcript scanning via RT-PCR included Cortex, Liver, Brain Stem, Spinal Cord, Skeletal 
Muscle, Kidney, Midbrain, Hippocampus, Hypothalamus, Cerebellum, Heart. Actin 
expression was used as a control.  4 sets of potentially alternatively spliced regions were 
scanned using this method, Cacna1d E8-11, E12-E15, E32-E36, and E46-E48. Primer 
sequences for transcript scanning were as follows: E8F1 (5’ TTT GCC TTT GCC ATG 
CTC ACT G 3’), E11R1 (5’ TGG AAA TCT CCA CGA GCT TTA GCC), E12F1 (ACC 
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AGC GAG ACT GAA TCT GTC AAC), E15 R1 (CCA GGA CAA TCA CCA GCC AGT 
AAA), E32F1 (AGG GGT CTT CAC TGT TGA GAT GGT). E36R1 (ACC AAC CGC 
ATC ACT CGG AAA A), E46 F1 (ATG CCA CCT GCA AGT GAT ACT GAG), and 
E48 R1 (CAG GAT CTT CAC GGC AAA TGG T). RT-PCR products were run on a 2% 
agarose gel with GelRed (Biotium) in 1X Tris base acetic acid EDTA (TAE) and purified 
using the manufacturer’s protocol from the GeneJET Gel Extraction Kit (Thermo 
Scientific). 50X TAE stock solution was prepared using 242g tris base, 57.1mL glacial 
acetic acid, 100mL 0.5M EDTA, and distilled water up to 1L before being subjected to 
sterilization via autoclave.  
 
Molecular TOPO Cloning Reaction and Transformation of cDNA: To analyze gel 
purified transcripts, we cloned our desired cDNA sequences using the TOPO cloning kit 
(Thermo Scientific). As per the manufacturer’s protocol, we added ~200-400 ng of gel 
purified DNA to 1µL of the TOPO cloning vector and 1µL of the manufacturer’s salt 
solution for a total reaction volume of 6µL. We then flicked the solution tubes 2-3 times 
(instead of vortexing due to the small volume of the solution) and incubated the final 
mixture for 5 minutes at room temperature. At this time, chemically competent One Shot 
MAX Efficiency DH5a E. Coli cells (Thermo Scientific) were thawed on ice for ~10 
minutes. Then, 2µL of the TOPO cloning reaction were added to the cells and the resultant 
solution was incubated on ice for 30 minutes. The E. Coli cells were heat shocked at 42 °C 
for 30 seconds. Then, 250µL of SOC medium were added to the cells for a 1 hour, 37°C, 
250rpm outgrowth incubation. This outgrowth is necessary for the proper expression of 
10 
   
 
antibiotic resistance within the E. Coli cells.  The resulting cells were then plated onto LB 
agar plates with standard concentrations of ampicillin.   
Miniprep DNA Purification and Diagnostic Digestion: Individually-picked E. Coli 
colonies were suspended in 5mL of LB media with standard concentrations of ampicillin 
and grown overnight at 37 °C, 250 rpm. Plasmid DNA extraction was done using the 
GeneJETPlasmid Miniprep Kit (Thermo Scientific). Cells were pelleted for 15 minutes at 
4,000 rpm and the supernatant was discarded. The cell pellet was then resuspended using 
250µL of RES Solution. Bacterial cells were lysed with 250µL of Lysis Solution and then 
neutralized with 350µL of NEU Solution. The neutralized cells were centrifuged at 14,500 
rpm for 5 minutes. The resulting supernatant was decanted onto the manufacturer’s column 
filter and purified with two rounds of 500µL of Wash Solution using a vacuum manifold. 
The filtrate was then eluted with 35-50µL of elution buffer and DNA yields were measured 
via spectrometry. We verified the presence of an insert of the expected size via a diagnostic 
restriction enzyme digestion with the enzyme EcoRI (New England Biolabs). This digest 
was done using 0.5µL of 20 units/µL EcoRI, 200-300ng of DNA, 1µL of 10X CutSmart 
Buffer (New England Biolabs), and 9.5 µL of distilled water. This digestion was loaded 
onto a 2% agarose gel in 1X Tris-Borate-EDTA (TBE) and purified plasmids with the 
presence of an insert of the expected size were subsequently sent for DNA sequencing. 5X 
TBE stock solution was prepared using 60.55g Tris Base, 30.9g Boric Acid, 20mL of 0.5M 
EDTA, and distilled water up to 1L before being subjected to sterilization via autoclave.    
Generation of Minigene Constructs. To generate minigene constructs containing our 
exons of interest, we performed genomic PCR using 0.3 µL of 2 units/µL Q5 High-Fidelity 
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DNA Polymerase (New England Biolabs), 1ng of genomic mouse DNA, 10µL of 5X Q5 
Reaction Buffer (New England Biolabs), 2.5µL of 10µM of each forward and reverse 
primer designed to amplify our respective regions of interest, 1µL of 10mM dNTP, and 
22.7µL of DNase-free water for a total reaction volume of 50µL. PCR conditions were as 
follows: 30 cycles, 66°C annealing temperature, and 2 minutes and 30 seconds of extension 
time. The following primer sequences were used to obtain clones of each desired genomic 
region: I12F1 (ACA GTG GAA TTC GAT CAG CTG TGC TCC AAC A), I13R1 (ACA 
GTG CTC GAG CTT CTC CTT TCC CTC CCT CTA), I32F1 (ACA GTG GGA ATT 
CAG GCA GGC AGC CAT TAG CCA TTAG), I34R1 (ACA GTG CTC GAG ATG AAG 
CCT GGG TTC CAT AG), I34F1 (ACA GTG GAA TTC CCG TGG AGA TAG GAG 
AAA CAA C), I35R1 (ACA GTG CTC GAG GTG ACA GAG GTG AGA ACT GAA G), 
I46F1 (ACA GTG GAA TTC CCA ACT AGG CCA TCT TCT GAT AC), and I47R1 
(ACA GTG GGA TCC GCC CTA TGT CGG AAC ACT ATT T) . The PCR products 
were then gel purified and digested with the restriction enzymes relevant to their sequences. 
For our E13, E33-E34, and E35 minigenes we did a double digest using 0.5µL each of 20 
units/µL EcoRI and 20 units/µL of XhoI (New England Biolabs), 200-400ng of DNA, 8.5 
µL of distilled water, and 1 µL of 10X CutSmart Buffer for a total reaction volume of 
10µL. For our E47 minigene construction, we used the same protocol but used 20units/µL 
BamHI (New England Biolabs) instead of Xho1. We then ligated these digested inserts 
with digested pSPL3 vector. 1µL of 400 units/µL ofT4 DNA Ligase (New England 
Biolabs), 2µL of 10X T4 DNA Ligase Buffer (New England Biolabs), and appropriate 
amounts of Insert, Vector, and distilled water in accordance with the NEBioCalculator 
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were used for the ligation reaction. Ligated products were transformed into One Shot 
TOP10 competent cells (Thermo Scientific). 
Transformation of Ligated Products of Minigene Construction. 5µL of ligated DNA 
was inserted into thawed (~10 minutes) TOP10 competent cells. The resulting solution was 
incubated for 30 minutes on ice and then subjugated to 42°C heat shock for 30 seconds. 
950µL of SOC Medium were then added to the cells for a 1-hour outgrowth incubation at 
37°C and 250rpm. The resulting E. Coli were propagated onto select LB agar plates with 
standard concentrations of ampicillin.   
Minigene Transfection.  24 hours before minigene transfection, ~500,000 HEK 293T 
cells were seeded per each well of a 6 well-plate. For the transfection, 500ng of minigene 
DNA was co-transfected with 0ng, 500ng, and 1,500ng of expression vector containing the 
appropriate SF to yield variable dose-dependent ratios of 0X, 1X, and 4X amounts of SF 
DNA per each minigene. pcDNA3 (Invitrogen) was used as empty vector to keep the total 
amount of transfected DNA to 2.5µg per well. HEK 293T cells were subsequently 
incubated in Dulbecco’s modified eagle’s medium (DMEM; VWR) for 48 hours after the 
transfection at 37 °C and 5% CO2.  
RNA Purification and DNase Digestion: 48 hours after the transfection, a total RNA 
extraction was performed directly on the transfected cells using 500µl of RiboZol 
(AMRESCO) lyse solution per each well. Lysed cells underwent phase extraction with 
100µL of chloroform. Subsequently, the RNA phase was precipitated with a combination 
of 250µL of isopropanol and 40µg of RNA-grade glycogen (Thermo Scientific) and 
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washed with 500µL of 75% EtOH. 500ng of purified RNA was then digested with DNase 
using 1µL of 2units/µL TURBO DNase (Thermo Scientific), 5µL of 10X TURBO DNase 
Buffer (Thermo Scientific), and DEPC water to a total reaction volume of 50µL. For the 
digestion, the solution was incubated at 37°C for 1 hour.  After the addition of 10µL of 
DNase Inactivation Reagent, the resultant solution was centrifuged at 10,000rpm for 90 
seconds and supernatant RNA was transferred into a fresh, sterile tube. The digested RNA 
was stored at -80 °C.   
Post-transfection semi-quantitative RT-PCR: After the full RNA homogenization a 3 
phase RT-PCR was performed with the same “phase 1” and “phase 2” steps as mentioned 
above. Phase 3 however, was now performed using 0.4µL of 5units/µL Dream Taq Hot 
Start DNA Polymerase (Thermo Scientific), 0.5µL of 10X Dream Taq Buffer (Thermo 
Scientific), 1µL each of 10µM forward and reverse primers specific to the pSPL3 
constitutive exons V1 and V2, 1µL of dNTPs, 4µL of RT product, and 37.6µL of DEPC 
water. The resulting RT-PCR products were run on a 2.5% agarose gel in 1X TAE for 
analysis. RT-PCR products were cloned and sequenced following the TOPO cloning 
procedures mentioned above.  
Quantification using ImageJ: The quantification of the regulation of E47 expression by 
certain SF was performed using ImageJ software (Rasband, 1997-2018). This 
quantification was done by calculating the ratio of the band intensities of both the E47-
inclusion band and the E47-skipping band for each set of transfection assays for SF that 
regulate E47. The ratio of inclusion band over skipping band was calculated for each 
transfection (or gel lane). The calculated ratios for the first (0X), second (1X), and third 
14 
   
 
(2X) lane were then divided by the calculated ratio for the first (0X) lane, thus normalizing 
all the ratios by the first (0X) lane and providing a fold-change value. The resulting value 
therefore quantifies the expression of E47 in each lane relative to the 0X SF lane, which 
allows us to clearly see how that SF regulates E47.
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Chapter 3: Results  
Cacna1d Transcript Scanning. Via semi-quantitative RT-PCR transcript scanning, we 
were able to characterize 4 alternatively spliced regions of Cacna1d: Cacn1d E8-E11, 
Cacna1d E12-15, Cacna1d E32-36, and Cacna1d E46-48. As seen in Figure 2, our 
transcript scanning assay for Cacna1d E8-E11 defines E8 and E11 as constitutive and 
confirms 3 alternatively spliced variants at the N-terminus of Cav1.3 in the mouse. In the 
spinal cord, the top band seen in Figure 2 represents a splice variant that includes E8-E10-
E11. In the cerebellum, however, this band corresponds to the variant E8-E9-11. These two 
variants are seen as a band of the same size because E9 and E10 are exons of the same size. 
The bottom band variant includes E8, 10, and 11, and skips E9. As seen in Figure 2, the 
expression of these splice variants is significantly higher in CNS tissue samples when 
compared to non-CNS tissue samples.   
E8 E10 E11 




























































Figure 2 Semi-quantitative RT-PCR of Canca1d E8-E11. 2%TAE agarose gel.The top band seen at 
a high level of expression in all CNS tissue samples corresponds to  the variant E8-E10-E11 in the 
spinal cord and to the variant E8-E9-E11 in the cerebellum. Both of these variants are the same 
size, as E9 and E10 are the same size. The bottom band seen in the figure corresponds to the E8-
E11 variant  in mouse kidney.     
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As seen in Figure 3, our assay for Cacna1d E12-E15 defines E12 and E15 as 
constitutive. We were able to characterize 2 alternatively spliced variants within this 
region, confirming E13 as a cassette exon (Gehman et al 2011). The top band corresponds 
to a splice variant that includes E12, E14, and E15, and skips E13. The bottom band 
corresponds to a splice variant that includes all exons between 12 and 15. Figure 3 also 
shows that expression of these splice variants is significantly higher in CNS tissue samples 



























































300- E12 E13 E14 E15 
E12 E14 E15 
200- 
Figure 3 Semi-quantitative RT-PCR of Cacna1d E12-E15. 2% TAE agarose gel. The top band 
corresponds to the E12-E13-E14-E15 variant, and the bottom band corresponds to the E12-E14-E15 
variant. Both products appear to be expressed at higher levels in CNS tissue samples compared to non-
CNS tissue samples.  
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As seen in Figure 4, our assay for Cacna1d E32-E36 defines E32 and E36 as 
constitutive exons. We were able to characterize 5 alternatively spliced variants within this 
region, all of which we believe to be novel.  The top band corresponds to a splice variant 
that includes E32, E33, and E36, but skips E33 and E35. The middle band corresponds to 
a splice variant that includes E32, E33, E35, and E36 but skips E34. As E33 and E34 are 
the same size, this middle band also corresponds to a splice variant that includes E32, E34, 
E35, and E36, but skips E33. The bottom band corresponds to one splice variant that 
includes E32, E33, and E36 but skips E34 and E35 as well as another splice variant that 
includes E32, E34, and E36 but skips E33 and E35. This pattern of AS hints at the potential 
functionality of these isoforms in vivo, specifically possible isoform-dependent changes in 
E32 E33 E36 
E32 E34 E36 
E32 E33 E34 E35  E36 
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Figure 4 Semi-quantitative RT-PCR of Cacna1d E32-E36. 2% TAE agarose gel. Top band corresponds to E32-
E33-E34-E35-E36 variant. Middle band corresponds to both the E32-E33-E35-E36 variant and E34-E35-E36 
variant, as E33 and E34 are the same size. The bottom band corresponds to both the E32-E33-E36 variant and 
the E32-E34-E36 variant. All isoforms appear to be expressed at a higher level in CNS-derived tissue samples 
compared to non-CNS derived tissue samples.   
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electrophysiological properties of the channel. These possibilities will be explored in future 
works. Figure 4 also shows that expression of these splice variants is significantly higher 
in CNS tissue samples when compared to non-CNS tissue samples.  
As seen in Figure 5, our assay defines E46 and E48 as constitutive. We were able 
to characterize 2 alternatively spliced variants within these regions, both of which we 
believe to be novel. The top band corresponds to a splice variant includes all exons between 
46 and 48. The bottom band corresponds to a splice variant that skips E47. These results 
show E47 to be a cassette exon. Figure 5 also shows that expression of these splice variants 
is significantly higher in CNS tissue samples when compared to non-CNS tissue samples. 
Construction of Minigenes. We then set out to create minigene constructs of our 
alternatively spliced regions using the eukaryotic expression vector pSPL3 (see below). 
We set out to construct minigenes for E13, E33-E34, E35, and E47. We were unable to 
generate an E33-E34-E35 minigene. We were, however, able to construct minigenes for 
E13, E33-E34, E35, and E47.  




























































Figure 5 Semi-quantitative RT-PCR of Cacna1d E46-E48. 2% TAE agarose gel. Top band corresponds to 
E46-E47-E48 variant and bottom band corresponds to E46-E48 variant, characterizing E47 as a cassette 
exon. Both isoforms appear to be expressed at higher levels in CNS-derived tissue samples compared to non-
CNS derived tissue samples.  
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The pSPL3 vector that we used was generated by another group (Church et al 1994, Nisson 
et al 1994, Tompson and Young, 2017). It has the advantage that, by using 2 universal, 
constitutive exons (V1 and V2), it allows for the cloning of genomic regions that are 
smaller than the ones we would have to clone if we were to include the entire genomic 
region from the constitutive exon upstream of the alternatively spliced exon(s) to the 
constitutive exon downstream of the alternatively spliced exon(s). Moreover, the use of the 
same constitutive exons in all minigene constructs allows for more uniformity, as it 
excludes variability that could potentially arise from the use of gene-specific constitutive 
exons which would be different from minigene to minigene. With pSPL3 we can clone the 
intronic region surrounding the alternative exon(s) only, which is especially important to 
Figure 6 Minigene assay strategy. pSPL3 vector contains an artificial gene with an S40 promoter and 2 
universally expressed constitutive exons, V1 and V2. SV40 Promoter is used for enhanced expression in 
eukaryotic cell lines. Red arrows seen above V1 and below V2 correspond to the respective forward and 
reverse primers used for RT-PCR. The minigene constructs are co-transfected with mammalian expression 
vector encoding specific SF-such as Rbfox1- and cells are incubated for 48 hours. The final RT-PCR 
products from the extracted RNA should show one-two bands with a minigene containing a single cassette 
exon. One band should correspond to V1 and V2 (exon skipping), while the other band should correspond to 
V1-E-V2 (exon including), where E is a given exon of interest whose inclusion is promoted by the specific SF.  
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us because some of our introns are multiple kb, which makes cloning and co-transfection 
less technically feasible. This design is summarized graphically in Figure 6.  
Transfection of Cav1.3 Minigenes with Splicing Factors. To test whether the SF Nova-
1, Nova-2, Mbnl-2, Ptbp-2, and Rbfox-1 regulate AS in any of our minigenes, we co-
transfected variable SF-to-minigene ratios into HEK 293T cells (see Materials and 
Methods).  We were able to confirm that Rbfox-1 promotes the  inclusion of E13 (Gehman 
et al 2011) and characterize the novel inclusion of a cryptic exon (indicated as C) that is 
upregulated by each of Nova-1, Nova-2, and Ptbp-2 in a context- (i.e. minigene) specific 
manner (Figures 7,  8, 12, 13, and 14). Cryptic exon C results from retention of part of the 
intron sequence between the constitutive V1 and V2 exons that are part of the pSPL3 
vector, so that in this context this intron sequence is recognized as an exon by the 







Figure 7. Cacna1d E13 co-transfected with Nova-1 and Nova-2, respectively. 2.5% TAE Agarose Gel. SF are 
present in the following amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. E13w/Nova-1 and E13 w/Nova-2: 0X 
lane shows the constitutive V1-V2 exons, but does not show a top band, indicating the V1-C-V2 RT-PCR 
product is not detected in these conditions. The 1X lane shows the bottom band corresponding to the 
constitutive V1-V2 exons and also a top band corresponding to V1-C-V2 exons. The 4X lane has a bottom 
band corresponding to the constitutive V1-V2 exons and a top band corresponding to V1-C-V2. This indicates 
that both Nova-1 and Nova-2 promote the inclusion of C, as the addition of these SF increase the expression of 







4X 4X 1X 1X 0X 0X 
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Figure 8. Cacna1d E13 co-transfected with Ptbp-2. 2.5% TAE Agarose Gel. SF are present in the following 
amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. E13w/ Ptbp-2: 0X lane has a bottom band corresponding to the 
constitutive V1-V2 exons, but does not show a top band, indicating that V1-C-V2 is not present in these 
conditions. The 1X lane also has a bottom band corresponding to the constitutive V1-V2 exons, as well as a top 
band that corresponds to V1-C-V2.  The 4X lane has a bottom band corresponding to the constitutive V1-V2 
exons and a top band corresponding to V1-C-V2. This indicates that Ptbp-2 promotes the inclusion of C, as the 
addition of these SF increases the expression of the C-including variant in a dose-dependent manner.  
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E13 w/ Rbfox-1 E13 w/ Mbnl-2  
Figure 9 Cacna1d E13 co-transfected with Rbfox-1 and Mbnl-2, respectively. 2.5% TAE Agarose Gel. SF are 
present in the following amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. E13w/ Rbfox-1: 0X lane shows a bottom 
band that corresponds to the constitutive V1-V2 exons, but does not show other products, indicating that the V1-
E13-V2 variant is not present in these experimental conditions. The 1X lane shows a bottom band that 
corresponds to the constitutive V1-V2 exons and a middle band that corresponds to V1-C-V2. The 4X lane shows 
a bottom band corresponding to the constitutive V1-V2 exons and a middle band corresponding to V1-C-V2. 
While these experimental conditions promoted the inclusion of a different cryptic exon due to intron retention 
that came from both the vector intron between V1 and V2, as well as the intron for E13, we can still confirm that 
E13 inclusion is upregulated by Rbfox-1. E13 w/ Mbnl-2: The 0X,1X, and 4X lanes all show a bottom band that 
corresponds to the constitutive V1-V2 exons, and no top band is seen in these lanes. This indicates that Mbnl-2 
does not regulate E13. 
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We were also able to characterize the regulation of E33-E34 by Ptbp-2, Rbfox-1, 
and Mbnl-2. As seen in Figure 10, Ptbp-2, Rbfox-1, and Mbnl-2 all decrease the inclusion 
of E33-E34 and promote the inclusion of E33 over E34.   
 
Figure 10. Cacna1d E33-E34 co-transfected with Ptbp-2, Rbfox-1, and Mbnl-2, respectively. 2.5% TAE Agarose 
Gel. SF are present in the following amounts: Lane 1:,0X, Lane 2: 1X,  Lane 3: 4X. E33-34w/ Ptbp-2: 0X lane 
shows a bottom band that corresponds to the constitutive V1-V2 exons, a middle band that corresponds to V1-
E33/E34-V2, and a top band that corresponds to V1-E33-E34-V2. The 1X lane shows a bottom band that 
corresponds to the  constitutive V1-V2 exons, a middle band that corresponds to V1-E33/E34-V2, and a top band 
that corresponds to V1-E33-E34-V2.The 4X lane shows a bottom band corresponding to the constitutive V1-V2 
exons and a middle band corresponding to V1-E34-V2. The expression of the top band is markedly decreased 
when comparing the 1X to the 0X lane and the top band is not seen at all in the 4X lane. This indicates that Ptbp-
2 promotes the skipping of the E33-E34 variant. The identity of the middle band in the 4X lane is shifted from the 
V1-E33-V2 or V1-E34-V2 variants seen in the 0X lane, to V1-E34-V2. This indicates that Ptbp-2 promotes the 
inclusion of E33 over E43. E33-34w/ Rbfox-1: The 0X lane shows a bottom band that corresponds to the 
constitutive V1-V2 exons, a middle band that corresponds to V1-E33/E34-V2, and a top band that corresponds to 
V1-E33-E34-V2. The 1X lane shows a bottom band that corresponds to the constitutive V1-V2 exons, and a 
middle band that corresponds to V1-E33/E34-V2. The 4X lane shows a bottom band corresponding to the 
constitutive V1-V2 exons and a middle band corresponding to V1-E34-V2. The top band is not seen in the 1X and 
4X lanes, this indicates that Rbfox-1 promotes the skipping of the E33-E34 variant. The identity of the middle 
band in the 4X lane is shifted from the V1-E33-V2 or V1-E34-V2 variants seen in the 0X lane, to V1-E34-V2. 
This indicates that Rbfox-1 promotes the inclusion of E33 over E34. E33-34w/ Mbnl-2: 0X lane shows a bottom 
band that corresponds to the constitutive V1-V2 exons, a middle band that corresponds to V1-E33/E34-V2, and a 
top band that corresponds to V1-E33-E34-V2. The 1X lane shows a bottom band that corresponds to the  
constitutive V1-V2 exons, a middle band that corresponds to V1-E33/E34-V2, and a top band that corresponds to 
V1-E33-E34-V2.The 4X lane shows a bottom band corresponding to the constitutive V1-V2 exons and a middle 
band corresponding to V1-E34-V2. The identity of the middle band in the 4X lane is shifted from the V1-E33-V2 
or V1-E34-V2 variants seen in the 0X lane to V1-E34-V2. This indicates that Mbnl-2 promotes the inclusion of 
E33 over E34. The expression of the top band is markedly decreased when comparing the 1X and 4x lanes to the 
0X lane. This indicates that Mbnl-2 promotes the skipping of the E33-E34 variant in a dose-dependent manner.  
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We showed that E35 inclusion is upregulated by Rbfox-1, while it does not appear 
to be regulated by Mbnl-2, as seen in Figure 11. Figures 12 and 13 show that Ptbp-2 and 
Nova-2 promote the formation of cryptic exon C.  
 
 
Figure 12 Cacna1d E35 co-transfected with Nova-2. 2.5% TAE Agarose Gel. SF are present in the following 
amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. 0X lane shows a band that corresponds to the constitutive V1-V2 
exons and a top band corresponding to V1-C-V2. The, 1X and 4X lanes show a bottom band that corresponds to 
the constitutive V1-V2 exons and do not show a top band corresponding to V1-C-V2. Other bands seen in 1X and 
4X lane were not characterized. This indicates that in this minigene Nova-2 may promote skipping of cryptic 
exon C.  
 
V1 C V2 
V1 V2 
4X 1X 0X 
400- 
300- 
E35 w/ Nova-2  
Figure 11 Cacna1d E35 co-transfected with Rbfox-1 and Mbnl-2, respectively. 2.5% TAE Agarose Gel. SF are 
present in the following amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. E35w/ Rbfox-1: The 0X lane shows a 
bottom band that corresponds to the constitutive V1-V2 exons, but does not show a top band. The 1X lane shows 
a bottom band that corresponds to the constitutive V1-V2 exons and a top band that corresponds to V1-E35-V2. 
The 4X lane shows a bottom band that corresponds to the constitutive V1-V2 exons and a top band that 
corresponds to V1-E35-V2.  The inclusion of the V1-35-V2 top band in the 1X and 4X lanes and not in the 0X 
indicates that Rbfox-1 promotes the inclusion of E35. E35w/ Mbnl-2: the 0X,1X, and 4X lanes all show one band 
correspond to the constitutive V1-V2 exons, while none of them show E35 inclusion, indicating that Mbnl-2 does 
not regulate E35 in our minigene.  
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V1 E35 V2 




E35 w/ Rbfox-1  E35 w/ Mbnl-2  
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For E47, we were able to show that Nova-1 promotes inclusion of E47, while the 
role of Nova-2 is unclear, as seen in Figure 14. We were also able to show that while Ptbp-
2 promotes the formation of cryptic exon C, both Rbfox-1, and Mbnl-2 downregulated E47, 
as seen in Figure 15.  
Figure 13 Cacna1d E35 co-transfected with Ptbp-2. 2.5% TAE Agarose Gel SF are present in the following 
amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. 0X lane shows a band that corresponds to the constitutive V1-V2 
exons, but does not show a top band. The 1X lane shows a bottom band that corresponds to the constitutive V1-
V2 exons and a top band that corresponds to V1-C-V2. The 4X lane shows a bottom band that corresponds to the 
constitutive V1-V2 exons and a top band that corresponds to V1-C-V2. This indicates that Ptbp-2 promotes 
inclusion of C.  
V1 V2 
C V1 V2 
4X 1X 0X 
400- 
300- 
E35 w/ Ptbp-2  
V1 V2 
E47 V1 V2 
4X 4X 1X 1X 0X 0X 
300- 
250- 
E47 w/ Nova-1  E47 w/ Nova-2  
Figure 14 Cacna1d E47 co-transfected with Nova-1 and Nova-2, respectively. 2.5% TAE Agarose Gel. SF 
are present in the following amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. E47w/ Nova-1: The 0X lane 
shows a band that corresponds to the constitutive V1-V2 exons, and a top band that corresponds to V1-E47-
V2. The 1X lane shows a bottom band that corresponds to the constitutive V1-V2 exons and a top band that 
corresponds to V1-E47-V2. The 4X lane shows a bottom band corresponding to the constitutive V1-V2 
exons (bottom band) and a spliced (top) band corresponding to V1-E47-V2. The top band in the 4X lane is 
markedly increased when compared to the top band of both the 0X and 1X lanes, and the bottom band is 
markedly decreased in the 4X lane when compared to the 0X and 1X lane bands. This supports that even 
though E47 is seen expressed without Nova-1, that Nova-1 promotes the inclusion of E47. E47w/ Nova-2: 
No clear difference in expression is seen among the top band in each of the 0X,1X, and 4X lanes, indicating 
that Nova-2 does not conclusively regulate E47.  
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Quantification of E47 regulation by Nova-1, Rbfox-1, and Mbnl-2, as shown in 
Figure 16, shows that the SF have opposite effects on the inclusion of E47. This result 
suggests that these SF may antagonize each other in the CNS.   
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Figure 15 Cacna1d E47 co-transfected with Ptbp-2, Rbfox-1, and Mbn-l2, respectively. 2.5% 
TAE Agarose Gel. SF are present in the following amounts: Lane 1,0X; Lane 2 1X; Lane 3, 4X. 
E47w/ Ptbp-2: 0X lane shows a band that corresponds to the constitutive V1-V2 exons, and 
shows a top band that corresponds to V1-E47-V2. The 1X lane shows a bottom band that 
corresponds to the constitutive V1-V2 exons and a top band that corresponds to V1-C-V2. The 
4X lane shows a bottom band that corresponds to the constitutive V1-V2 exons and a top band 
that corresponds to V1-C-V2. E47w/ Rbfox-1: 0X lane shows a band that corresponds to the 
constitutive V1-V2 exons, and shows a top band that corresponds to V1-E47-V2. 1X lane shows a 
bottom band that corresponds to the constitutive V1-V2 exons and a top band that corresponds 
to V1-E47-V2, 4X lane shows a bottom band corresponding to the constitutive V1-V2 exons and 
a top band corresponding to V1-E47-V2. The top band in the 1X lane is markedly decreased 
when compared to both the 1X and 4X lane top bands. This supports that even though E47 is 
seen in the 4X lane of Rbfox-1, that Rbfox-1 promotes the skipping of E47. E47w/ Mbnl-2: The 
0X lane shows a band that corresponds to the constitutive V1-V2 exons and shows a top band 
that corresponds to V1-E47-V2.The 1X  lane shows a bottom band that corresponds to the  
constitutive V1-V2 exons and a top band that corresponds to V1-C-V2. The 4X lane shows a 
bottom band that corresponds to the constitutive V1-V2 exons and a top band corresponding to 
V1-C-V2. The top band in the 0X lane is markedly increased when compared to both the 1X and 
4X lane top bands. This supports that even though E47 is seen in the 4X Mbnl-2 lane, Mbn-l2 
promotes the skipping of E47.  
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Figure 16 Quantification of E47minigene splicing assay from Figure 15 with Nova-1, Rbfox-1, and Mbnl-2. The 
quantification was performed as described in the Material and Methods section. The data shows that Nova-1 
linearly promotes the inclusion of E47, while Rbfox-1 exponentially inhibits the inclusion of E47 and Mbnl-2 
linearly inhibits the inclusion of E47.  As described in the conclusion, this hints at a possible antagonist role of 
Nova-1 against both Rbfox-1 and Mbnl-2, or vice versa, in the CNS.    
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Chapter 4: Discussion  
Although the C-terminus of Cav1.3 is known to undergo extensive AS, how AS in 
this ion channel is regulated remains poorly understood. Our results serve to elucidate the 
mechanisms that regulate AS in Cav1.3. Previous reports have identified alternatively 
spliced variants in Cav1.3 that change the channel’s biophysical properties (Singh et al 
2008). These properties have been shown to have clinically significant roles in the 
development of neurological disorders such as ASD. Given that many of our characterized 
splice variants come from the C-terminus, it is possible that our characterized splice 
isoforms cause shifts in biophysical properties. This possibility will be tested in future 
work.  
Our results show that alternatively spliced variants between E8-E11, E12-E15, 
E32-E36, and E46-E48 are more heavily expressed in CNS tissue samples when compared 
to non-CNS tissue samples. This distribution shows the important role that Cav1.3 splice 
isoforms may have in neural physiology.  
We also found regulation of our splice variants by the SF Nova-1, Ptbp-2, Rbfox-
1, and Mbnl-2. As we continue to characterize the regulation of AS of Cacna1d, we gain a 
better understanding of the RNA-protein networks seen at the level of pre-mRNA. Protein-
RNA networks regulate the promotion and skipping of alternatively spliced exons in 
Cacna1d, where AS has been shown to regulate dendritic spine morphology (Stanika et al 
2016) . The upkeep of this morphology is significant for Parkinson’s Disease. The results 
presented in Figure 16 suggest a possible antagonist role between Nova-1 and both Rbfox-
1 and Mbnl-2 in the CNS, where for example Nova-1 promotes the inclusion of E47, while 
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Rbfox-1 and Mbnl-2 promote the skipping of E47. We also characterize dual functionality 
of Rbfox-1 in the promotion both the skipping and inclusion of different exons of Cav1.3. 
While it promotes the inclusion of E35, it also promotes the skipping of E47.  
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Chapter 5: Future works 
As we were able to characterize the regulation of wildtype minigenes by certain 
SFs, we now want to create mutants within our putative intronic cis-acting regulatory 
elements to see if these mutations abolish splicing. At the level of the SF, we want to mutate 
certain SF amino acids to see if these mutations abolish the regulation of splicing seen in 
the WT variants of these SF. 
As many of our co-transfections revealed the inclusion of cryptic exon C due to 
partial intronic retention between constitutive exons V1 and V2 of the pSPL3 vector, we 
also hope to create a new vector, pSPL4, that still works as an exon trapping vector but 
does not include C.  
As previous studies have shown that AS events in Cav1.3 can cause significant 
changes in electrophysiological properties, we plan to characterize the potential changes in 
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